Biopharm: Two VP of Sales for a total of 35 reps ?

[anonymous]

What a decision!

In Biopharm, they recently broke one Sales VP job into two: one for growth hormone, one for hemophilia.

1. Each 'field force' has about 35 reps. That warrants a separate VP ? Diabetes sales VPs have up to 1,000 people in their line of management. What a joke.

2. Growth hormone is completely commoditized. This happened years before insulin became commoditized. Completely contract driven. HGH is HGH, period, no difference, no clinical trials.

3. Hemophilia: NovoSeven RT is flat, and facing severe competition.

ET needs to answer how did you approve additional Sales VP positions along with the VP and Sr. Director roles to be back filled.

That whole thing needs to be undone, and then some.

Another example of ineptness from alleged leadership.

 

[anonymous]

What a decision!

In Biopharm, they recently broke one Sales VP job into two: one for growth hormone, one for hemophilia.

1. Each 'field force' has about 35 reps. That warrants a separate VP ? Diabetes sales VPs have up to 1,000 people in their line of management. What a joke.

2. Growth hormone is completely commoditized. This happened years before insulin became commoditized. Completely contract driven. HGH is HGH, period, no difference, no clinical trials.

3. Hemophilia: NovoSeven RT is flat, and facing severe competition.

ET needs to answer how did you approve additional Sales VP positions along with the VP and Sr. Director roles to be back filled.

That whole thing needs to be undone, and then some.

Another example of ineptness from alleged leadership.

Diabetes has how many layers of reps, managers, DE's? NovoLog, really? Levemir and Tresiba with a biosimilar from Lilly coming in December? Looks like a lot of fat there to trim!

 

[anonymous]

agreed, fat there too, but two VPs of sales ?

Much more volume and upside

 

[anonymous]

What a decision!

In Biopharm, they recently broke one Sales VP job into two: one for growth hormone, one for hemophilia.

1. Each 'field force' has about 35 reps. That warrants a separate VP ? Diabetes sales VPs have up to 1,000 people in their line of management. What a joke.

2. Growth hormone is completely commoditized. This happened years before insulin became commoditized. Completely contract driven. HGH is HGH, period, no difference, no clinical trials.

3. Hemophilia: NovoSeven RT is flat, and facing severe competition.

ET needs to answer how did you approve additional Sales VP positions along with the VP and Sr. Director roles to be back filled.

That whole thing needs to be undone, and then some.

Another example of ineptness from alleged leadership.

You don't get it, do you? When profits are fat, the more regional managers and VPs someone has underneath them, the more "important" they are to the organization. (And on a personal note, the more attractive their CV appears to Sanofi or Novartis when they get let go from here.)

I wouldbt be surprised that as we speak, senior level directors and ET members are fighting over every.single.one. of "their people".

I foresee a shuffling of the deck, just so that the new guy can prove that he's done something. Snip-snip here, snip there, and then wait a year to see if the new Basaglar formularies have a negative impact on Tresiba numbers and the Xultophy launch. If Victoza growth slows, or the two newest products fail to meet expectations by the end of next year? Get your family ready for a big decrease in income, cuz we'll be cutting down.

 

[anonymous]

Biopharm is a tough place to be these days. Major profit pressure when generic Vagifem hits. No chance to make it up from hGH, N7 or N8. No new products coming. The Sales VPs have a tough job ahead.

 

[anonymous]

What a decision!

In Biopharm, they recently broke one Sales VP job into two: one for growth hormone, one for hemophilia.

1. Each 'field force' has about 35 reps. That warrants a separate VP ? Diabetes sales VPs have up to 1,000 people in their line of management. What a joke.

2. Growth hormone is completely commoditized. This happened years before insulin became commoditized. Completely contract driven. HGH is HGH, period, no difference, no clinical trials.

3. Hemophilia: NovoSeven RT is flat, and facing severe competition.

ET needs to answer how did you approve additional Sales VP positions along with the VP and Sr. Director roles to be back filled.

That whole thing needs to be undone, and then some.

Another example of ineptness from alleged leadership.

 

[anonymous]

Each BioPharm "rep" generates an average of $20mm/year. What about your reps? Regardless the franchise, we outperform Diabetes at every level. Sorry to burst your bubble, Sport.....

 

[anonymous]

Each BioPharm "rep" generates an average of $20mm/year. What about your reps? Regardless the franchise, we outperform Diabetes at every level. Sorry to burst your bubble, Sport.....

Does that mean you need to VPs? NO

 

[anonymous]

agreed, fat there too, but two VPs of sales ?

Much more volume and upside

one of market access, one of sales.

 

[anonymous]

business isn't run on revenue-per-rep you dumbass. In biopharm's case, it'd be more ludicrous to have any more headcount.

with only a few hundred HTCs in the US, with the cost of the drug well north of $1,000 per mcg, with the only rFVII product in the market and less than 2,000 inhibitor patients NATIONALLY, it's about how efficiently you can harvest a patient. Ps knucklehead, what's the compliance and persistency rates with a drug that's saving a patient from a brain bleed? 100% or you die. Not true with a T2 patient. I'd argue strongly and successfully that a biopharm rep truly impacts much less than 5% of the business. So yeah, I know a little about hemophilia.

HGH is completely commoditized. Full stop.

You don't know jack.

 

[anonymous]

business isn't run on revenue-per-rep you dumbass. In biopharm's case, it'd be more ludicrous to have any more headcount.

with only a few hundred HTCs in the US, with the cost of the drug well north of $1,000 per mcg, with the only rFVII product in the market and less than 2,000 inhibitor patients NATIONALLY, it's about how efficiently you can harvest a patient. Ps knucklehead, what's the compliance and persistency rates with a drug that's saving a patient from a brain bleed? 100% or you die. Not true with a T2 patient. I'd argue strongly and successfully that a biopharm rep truly impacts much less than 5% of the business. So yeah, I know a little about hemophilia.

HGH is completely commoditized. Full stop.

You don't know jack.

Totally accurate.

Plus, the company doesn't care about total revenue, it cares about growth. That $20m ain't going anywhere if they cut the rep.

The biopharm division was a glamor position that was great when times were good...just like all these VPs and ADs and the title inflation culture. We look like a god damn Soviet Army...just need the ET to roll out with a novo polo full of medals.

 

[anonymous]

youre 100% right - and biopharm was a cash darling which funded diabetes growth for years.

Yes, not a farm mcg of N7 for Nirditropin would be missed if the reps went away.

 

[anonymous]

Biopharm is a classic mature business with OLD undifferentiated products. Hardly an exciting, innovative biotech business. Sales and marketing have little impact. It is all about giving away more profit each contracting cycle in order to maintain formulary position.

No vision or growth plan. This division will continue to pressure Novo earnings. More of a liability than an asset. Now another VP?

 

[anonymous]

Biopharm is a classic mature business with OLD undifferentiated products. Hardly an exciting, innovative biotech business. Sales and marketing have little impact. It is all about giving away more profit each contracting cycle in order to maintain formulary position.

No vision or growth plan. This division will continue to pressure Novo earnings. More of a liability than an asset. Now another VP?

Actually, two VPs were requested, but only one was funded. I can't say any more than that.

 

[anonymous]

That doesn't make any sense.

There's NO WAY that someone is in a role that's not approved/funded. Period.

 

[anonymous]

What is happening in Biopharm?
I heard mass panic.
Will Novo try to divest (like Biogen hemophilia)?

 

[anonymous]

What is happening in Biopharm?
I heard mass panic.
Will Novo try to divest (like Biogen hemophilia)?

That's actually not a crazy idea.

 

[anonymous]

It's Toast as it's own division ...not sure where Eddie will land or if retirement package will be good enough. All going to be absorbed into new present business model. The beginning Of the end. Bye bye biopharm. Hello severance!

 

[anonymous]

What a lost opportunity. Biopharm had so much potential, but no strategy. Never convinced the NN Gods that it could be more than just a profit center.

 

[anonymous]

It's Toast as it's own division ...not sure where Eddie will land or if retirement package will be good enough. All going to be absorbed into new present business model. The beginning Of the end. Bye bye biopharm. Hello severance!